Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) - Total Assets
Based on the latest financial reports, Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) holds total assets worth CN¥2.30 Billion CNY (≈ $336.59 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 688621 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Beijing Sun Novo Pharmaceutical Research Co Ltd - Total Assets Trend (2017–2025)
This chart illustrates how Beijing Sun Novo Pharmaceutical Research Co Ltd's total assets have evolved over time, based on quarterly financial data. Check 688621 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Beijing Sun Novo Pharmaceutical Research Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Beijing Sun Novo Pharmaceutical Research Co Ltd's total assets of CN¥2.30 Billion consist of 76.2% current assets and 23.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 20.2% |
| Accounts Receivable | CN¥581.78 Million | 25.5% |
| Inventory | CN¥14.03 Million | 0.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥4.73 Million | 0.2% |
| Goodwill | CN¥20.51 Million | 0.9% |
Asset Composition Trend (2017–2025)
This chart illustrates how Beijing Sun Novo Pharmaceutical Research Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Beijing Sun Novo Pharmaceutical Research (688621) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Sun Novo Pharmaceutical Research Co Ltd's current assets represent 76.2% of total assets in 2025, an increase from 59.8% in 2017.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2025, up from 5.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 25.5% of total assets.
Beijing Sun Novo Pharmaceutical Research Co Ltd Competitors by Total Assets
Key competitors of Beijing Sun Novo Pharmaceutical Research Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Eris Lifesciences Limited
NSE:ERIS
|
India | Rs71.60 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Lotus Pharmaceutical Co Ltd
TW:1795
|
Taiwan | NT$106.15 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
Beijing Sun Novo Pharmaceutical Research Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.79 | 1.64 | 3.65 |
| Quick Ratio | 1.77 | 1.62 | 3.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥758.31 Million | CN¥643.92 Million | CN¥580.88 Million |
Beijing Sun Novo Pharmaceutical Research Co Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing Sun Novo Pharmaceutical Research Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.57 |
| Latest Market Cap to Assets Ratio | 0.38 |
| Asset Growth Rate (YoY) | 15.0% |
| Total Assets | CN¥2.28 Billion |
| Market Capitalization | $858.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Sun Novo Pharmaceutical Research Co Ltd's assets below their book value (0.38x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Beijing Sun Novo Pharmaceutical Research Co Ltd's assets grew by 15.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
The table below shows the annual total assets of Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.28 Billion ≈ $334.34 Million |
+14.97% |
| 2024-12-31 | CN¥1.99 Billion ≈ $290.81 Million |
+6.67% |
| 2023-12-31 | CN¥1.86 Billion ≈ $272.62 Million |
+27.33% |
| 2022-12-31 | CN¥1.46 Billion ≈ $214.10 Million |
+17.74% |
| 2021-12-31 | CN¥1.24 Billion ≈ $181.84 Million |
+222.89% |
| 2020-12-31 | CN¥384.86 Million ≈ $56.32 Million |
+34.79% |
| 2019-12-31 | CN¥285.51 Million ≈ $41.78 Million |
+41.70% |
| 2018-12-31 | CN¥201.50 Million ≈ $29.49 Million |
+83.06% |
| 2017-12-31 | CN¥110.07 Million ≈ $16.11 Million |
-- |
About Beijing Sun Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform;… Read more